Balanced news tone
News Sentiment
2566 sentiment intelligence
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
58
Balanced news tone
2 relevant articles
News tone and price action are not far from neutral.
58/100 classification confidence.
directly relevant articles
high-authority source matches
-3.6% over one week, +23.3% over four weeks, trend inactive, and below fair value.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. commences an Equity Buyback Plan for 24,151,640 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2026.
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Capital return
58/100 classification
One-week reaction
-3.6%
Price reacting lower
Trend fit
Trend inactive
23.3% over four weeks
Fair value
-20.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
1
Neutral
1
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
marketscreener.com
Direct company coverage
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. commences an Equity Buyback Plan for 24,151,640 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2026.
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 07:00
- Source
- marketscreener.com
BioWorld News
Direct company coverage
Jiuyuan Gene raises HKD$485M in Hong Kong IPO
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Dec 2024 08:00
- Source
- BioWorld News